These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24366939)

  • 1. Targeted cancer therapy: from bench to bedside to patient.
    Gellad WF
    J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 4. With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
    Tuma RS
    J Natl Cancer Inst; 2007 Feb; 99(3):192-4. PubMed ID: 17284712
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
    Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
    Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
    Soysal T; Eskazan AE; Ar MC
    Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Position paper on imatinib mesylate in chronic myeloid leukaemia.
    O'Brien SG; Rule SA
    Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
    Conti RM; Padula WV; Larson RA
    Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
    Garside R; Round A; Dalziel K; Stein K; Royle P
    Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic myelogenous leukemia.
    Klemm J; Mehr SR
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP105-7. PubMed ID: 22642273
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NICE backs leukaemia drug after manufacturer drops price.
    Wise J
    BMJ; 2012 Mar; 344():e2274. PubMed ID: 22442356
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib for chronic myeloid leukaemia: a NICE mess.
    O'Brien SG
    Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Jabbour EJ; Kantarjian H; Eliasson L; Cornelison AM; Marin D
    Am J Hematol; 2012 Jul; 87(7):687-91. PubMed ID: 22473898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 19. [Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate].
    Scopel CT; Chaves GC
    Cad Saude Publica; 2015 Mar; 31(3):575-85. PubMed ID: 25859724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.